Manuel Rodríguez-López, Servicio de Hematología y Hemoterapia, Hospital Universitario Álvaro Cunqueiro, Instituto de Investigación Sanitaria Galicia Sur, EOXI Vigo, Vigo, España
Elena Y. Romero-Ventosa, Servicio de Farmacia Hospitalaria, Hospital Universitario Álvaro Cunqueiro, Instituto de Investigación Sanitaria Galicia Sur, EOXI Vigo, Vigo, España
Raquel Ocampo-Martínez, Servicio de Hematología y Hemoterapia, Hospital Universitario Álvaro Cunqueiro, Instituto de Investigación Sanitaria Galicia Sur, EOXI Vigo, Vigo, España
Gala Cabirta-Touzon, Servicio de Hematología y Hemoterapia, Hospital Universitario Álvaro Cunqueiro, EOXI Vigo, Instituto de Investigación Sanitaria Galicia-Sur (IISGS), Vigo, España
Antia Amoedo-Bastos, Servicio de Hematología y Hemoterapia, Hospital Universitario Álvaro Cunqueiro, Instituto de Investigación Sanitaria Galicia Sur, EOXI Vigo, Vigo, España
Carmen Albo-López, Servicio de Hematología y Hemoterapia, Hospital Universitario Álvaro Cunqueiro, Instituto de Investigación Sanitaria Galicia Sur, EOXI Vigo, Vigo, España
Introduction: Thrompopoietin receptor agonists (TPO-RAs) have transformed the treatment of ITP. Avatrombopag, a second-generation oral TPO-RA, demonstrated superiority over placebo in clinical trials. Objective: To evaluate the efficiency of the use of avatrombopag in a tertiary care hospital. Materials and methods: Retrospective analysis of 22 patients with ITP treated with avatrombopag. Results: Sixty-eight-point two percent had primary ITP; 81.8% had received other TPO-RA. Significant improvement in platelet count was observed (from 51,000/μl to > 140,000/μl; p = 0.0018). The final mean dose was 143.97 mg/week, reduced in specific subgroups. Average weekly cost per patient decreased by 62.45% (from € 703 to € 264). Conclusions: The study reveals a favorable clinical and economic impact. Reduction of doses and concomitant treatment suggests greater therapeutic efficiency in early stages. Avatrombopag shows high clinical efficacy and a notable cost reduction in ITP.
Keywords: Avatrombopag. Idiopathic thrombocytopenic purpura (ITP). Efficacy. Cost-effectiveness. Thrombopoietin agonists (TPO-RA).